Monday, December 21, 2020 4:32:37 PM
At an earlier stage in the months following the big downfall of Amarin after the 9th Circuit loss marts 30 2020 - I had an Idea to try to reach out to Potus and WH - telling the story of Vascepa - and how 'the destroyed patents' undermined Amarins strength to bring ' this vunder Drug to the CDV populations that needs it.
My background for possible hoping being heard is that I happen to be a big supporter of Potus since the start 2015 - and has sent many tweets earlier regarding this' and that'.
http://talksense.dk/
Because of Covid and Election coming up - I gave up on the idea.
-------------------------
Now we have a New situation.
1. T's is as it looks right now leaving WH in 30 days.
2. As debated here much since the fantastic Covid results from trial in Canada - reported the december 12 (9 days ago) - this information needs to be brought 'to needing' patients all over USA (and big parts of rest of the world ultimately as well).
3. Maybe timing could be successful - 'for getting WH and Potus involved in such a positive cause (saving sick covid patients) given the fact that that there is only days left to 'reach out - on top of vaccines' to people already sick with and needing long term solution to stay healthy.
4. These days 'everything is politics' - Giving Potus a chance to bring something to the fight against long term effects for people who is/or has been suffering fron Covid - would be a great way to close 'this bad chapter for Potus for now. And we at AMRN iHub know' - that Vascepa is 'the real deal' - that truely does wonders for CDV patients - and now also 'as expected' for Covid patients.
----------------------------------
Everything to gain - to try to 'reach out to WH. Possibly hundreds of people sending the same message:
Tell the population of USA - that Vascepa is the 'proven long term solution' for a better health - with very little side effects.
----------------------------------
If anyone thinks this is worth a try - please respond. And 'if so' we need someone with weight and insight - to explain to WH and Potus - why this is Important enough - to 'Inform the entire population of USA' about this great treatment for recovering Covid patients - and to 'people at risk' - effectively diminishing their risk if infected by Covid.
----------------------------------
If there is backup for 'to try this' I would send it also to T Junior - Eric - Melania - the complete Fox News T backups' Greg - Watters - Hannity - Ingraham etc.
Jasbg
NB: If decided to give this a try - the top would be someone like HK - put together - a short and precise document 'explaining 'why Vascepa has the potential to be part of the long term solution beating the covid-19 pandemic'.
My background for possible hoping being heard is that I happen to be a big supporter of Potus since the start 2015 - and has sent many tweets earlier regarding this' and that'.
http://talksense.dk/
Because of Covid and Election coming up - I gave up on the idea.
-------------------------
Now we have a New situation.
1. T's is as it looks right now leaving WH in 30 days.
2. As debated here much since the fantastic Covid results from trial in Canada - reported the december 12 (9 days ago) - this information needs to be brought 'to needing' patients all over USA (and big parts of rest of the world ultimately as well).
3. Maybe timing could be successful - 'for getting WH and Potus involved in such a positive cause (saving sick covid patients) given the fact that that there is only days left to 'reach out - on top of vaccines' to people already sick with and needing long term solution to stay healthy.
4. These days 'everything is politics' - Giving Potus a chance to bring something to the fight against long term effects for people who is/or has been suffering fron Covid - would be a great way to close 'this bad chapter for Potus for now. And we at AMRN iHub know' - that Vascepa is 'the real deal' - that truely does wonders for CDV patients - and now also 'as expected' for Covid patients.
----------------------------------
Everything to gain - to try to 'reach out to WH. Possibly hundreds of people sending the same message:
Tell the population of USA - that Vascepa is the 'proven long term solution' for a better health - with very little side effects.
----------------------------------
If anyone thinks this is worth a try - please respond. And 'if so' we need someone with weight and insight - to explain to WH and Potus - why this is Important enough - to 'Inform the entire population of USA' about this great treatment for recovering Covid patients - and to 'people at risk' - effectively diminishing their risk if infected by Covid.
----------------------------------
If there is backup for 'to try this' I would send it also to T Junior - Eric - Melania - the complete Fox News T backups' Greg - Watters - Hannity - Ingraham etc.
Jasbg
NB: If decided to give this a try - the top would be someone like HK - put together - a short and precise document 'explaining 'why Vascepa has the potential to be part of the long term solution beating the covid-19 pandemic'.
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
